Tehran University of Medical Sciences

Science Communicator Platform

Share By
Deleterious Variants in the Autophagy-Related Gene Rb1cc1/Fip200 Impair Immunity to Sars-Cov-2 Publisher Pubmed



Hu L ; Van Der Sluis RM ; Castelino KB ; Zhang BC ; Ronit A ; Zillinger T ; Werner M ; Jorgensen SE ; Hansen AL ; Pedersen A ; Narita R ; Reinert LS ; Bundgaard B ; Helleberg M Show All Authors
Authors
  1. Hu L
  2. Van Der Sluis RM
  3. Castelino KB
  4. Zhang BC
  5. Ronit A
  6. Zillinger T
  7. Werner M
  8. Jorgensen SE
  9. Hansen AL
  10. Pedersen A
  11. Narita R
  12. Reinert LS
  13. Bundgaard B
  14. Helleberg M
  15. Benfield T
  16. Storgaard M
  17. Hansen KS
  18. Bodilsen J
  19. Zhang SY
  20. Zhang Q
  21. Zatz M
  22. Wauters J
  23. Von Bernuth H
  24. Vinh DC
  25. Vianna FSL
  26. Van De Beek D
  27. Uddin MJ
  28. Uddin KMF
  29. Turvey SE
  30. Trouilletassant S
  31. Tiberghien P
  32. Thorball C
  33. Temel SG
  34. Tayoun AA
  35. Tangye SG
  36. Tancevski I
  37. Su HC
  38. Spaan AN
  39. Soumelis V
  40. Solerpalacin P
  41. Snow AL
  42. Slaby O
  43. Shcherbina A
  44. Shahrooei M
  45. Seppanen MRJ
  46. Sediva A
  47. Sanchoshimizu V
  48. Rodriguezgallego C
  49. Resnick I
  50. Renia L
  51. Ramaswamy S
  52. Quintanamurci L
  53. Puel A
  54. Pujol A
  55. Prando C
  56. Planas AM
  57. Peter J
  58. Perlin DS
  59. Pereztur J
  60. De Diego RP
  61. Panhammarstrom Q
  62. Ozcelik F
  63. Ozcelik T
  64. Okamoto K
  65. Okada S
  66. Ofarrelly C
  67. Novelli G
  68. Novelli A
  69. Notarangelo LD
  70. Ng LFP
  71. Morio T
  72. Mironska K
  73. Milner JD
  74. Meyts I
  75. Mentre F
  76. Marodi L
  77. Mansouri D
  78. Mahevas M
  79. Lucas CL
  80. Ling Y
  81. Lau YL
  82. Ku CL
  83. Kisand K
  84. Karamitros T
  85. Kaja E
  86. Jouanguy E
  87. Itan Y
  88. Imai K
  89. Husebye E
  90. Hsieh EWY
  91. Heath JR
  92. Hammarstrom L
  93. Halwani R
  94. Hagin D
  95. Haerynck F
  96. Gut M
  97. Gorochov G
  98. Froidure A
  99. Franco JL
  100. Flores C
  101. Fellay J
  102. Espinosapadilla S
  103. Eloy P
  104. El Baghdadi J
  105. Duvlis S
  106. Duval X
  107. Dundar M
  108. Drolet BA
  109. Desai M
  110. Dalgard CL
  111. Cooper MA
  112. Constantinescu SN
  113. Condinoneto A
  114. Colobran R
  115. Cobat A
  116. Christodoulou J
  117. Casari G
  118. Bryceson Y
  119. Brodin P
  120. Bousfiha AA
  121. Borghesi A
  122. Bondarenko A
  123. Bolze A
  124. Bogunovic D
  125. Biggs CM
  126. Belot A
  127. Bastard P
  128. Feldman HB
  129. Arkin LM
  130. Arias AA
  131. Andreakos E
  132. Anderson MS
  133. Almulla F
  134. Almuhsen S
  135. Aiuti A
  136. Abel L
  137. Holm CK
  138. Cobat A
  139. Casanova JL
  140. Reggiori F
  141. Mari M
  142. Paludan SR
  143. Mogensen TH

Source: Nature Communications Published:2025


Abstract

The clinical outcome of SARS-CoV-2 infection spans from asymptomatic viral elimination to lethal COVID-19 pneumonia, which is due to type I interferon (IFN) deficiency in at least 15–20% of cases. We report two unrelated male patients with critical COVID-19 who are heterozygous for rare deleterious variants in RB1CC1, encoding the autophagy-related FIP200 protein. Airway epithelial cells genetically deprived of FIP200 or cell lines expressing the RB1CC1/FIP200 patient variants exhibit elevated SARS-CoV-2 replication and impaired autophagic flux. The antiviral function of FIP200 is independent of canonical autophagy and type I IFN, but involves the selective autophagy receptor NDP52. We identify a non-canonical function of FIP200 in a novel lysosomal degradation pathway, in which SARS-CoV-2 virions are targeted to single-membrane compartments for degradation of viral RNA in LC3B-positive acidified vesicles. This pathway is impaired in FIP200-deficient cells and in cells expressing FIP200 patient haplotypes. Collectively, we describe a cell-autonomous anti-SARS-CoV-2 restriction pathway, dependent on FIP200 and NDP52, and independent of canonical autophagy and type I IFN, which can underlie critical COVID-19 pneumonia. © The Author(s) 2025.